ABBV · 8-K · 20260731PR000023
Guidance / Outlook
AbbVie Inc. · 2026-07-31 · Importance 56 · Surprise 68 · In source text
AbbVie lowered its full-year 2026 adjusted diluted EPS guidance range from $13.91–$14.11 to $13.87–$14.07, a $0.04 reduction at the midpoint. The revised outlook includes a $0.14 per-share dilution from the proposed Apogee acquisition, which is expected to close in the third quarter of 2026. The dilution is partially offset by $0.10 of overperformance. Guidance also includes an unfavorable $0.58-per-share impact from acquired IPR&D and milestone expense incurred through the second quarter and excludes such expenses incurred after that period.
Key facts
- The proposed acquisition of Apogee Therapeutics is expected to be $0.14 dilutive to 2026 adjusted diluted EPS based upon an anticipated close in the third quarter of 2026. source
- The Apogee acquisition $0.14 dilution is partially offset by $0.10 of overperformance. source
- AbbVie updated 2026 adjusted diluted EPS guidance range from $13.91 - $14.11 to $13.87 - $14.07, reflecting a change of $0.04 at the midpoint. source
- Reported GAAP diluted EPS for the six months ended June 30, 2026: $2.42; adjusted diluted EPS: $6.30. source
- AbbVie will host an investor conference call on July 31, 2026 at 8:00 a.m. Central Time; archived edition will be available after 11:00 a.m. Central Time. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | committed | — | The proposed acquisition of Apogee Therapeutics is expected to be $0.14 dilutive to 2026 adjusted diluted EPS based upon an anticipated… |
| net_income | positive | committed | — | The Apogee acquisition $0.14 dilution is partially offset by $0.10 of overperformance. |
| net_income | negative | committed | — | AbbVie updated 2026 adjusted diluted EPS guidance range from $13.91 - $14.11 to $13.87 - $14.07, reflecting a change of $0.04 at the… |